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Research Article
Spinal direct current stimulation (tsDCS) in
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controlled crossover study
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Alessio Di Fonzo4, Sara Bonato4, Filippo Cogiamanian1, Francesca Cortese1,
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Pisa, Italy, 3“Aldo Ravelli” Center for Neurotechnology and Experiental Brain Therapeutics, Department of Health
Sciences, University of Milan & ASST Santi Paolo e Carlo, Milan, Italy, 4Neurology Unit, Fondazione IRCCS Ca’
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Objective: Hereditary spastic paraplegia (HSP) represents a heterogeneous group of neurodegenerative
diseases characterized by progressive spasticity and lower limb weakness. We assessed the effects of
transcutaneous spinal direct current stimulation (tsDCS) in HSP.
Design: A double-blind, randomized, crossover and sham-controlled study.
Setting: Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan.
Participants: eleven patients with HSP (six men, mean age ± SD: 37.3 ± 8.1 years), eight affected by spastin/
SPG4,1 by atlastin1/SPG3a, 1 by paraplegin/SPG7 and 1 by ZFYVE26/SPG15.
Interventions: tsDCS (anodal or sham, 2.0 mA, 20’, five days) delivered over the thoracic spinal cord (T10-T12).
Outcome measures: Motor-evoked potentials (MEPs), the H-reflex (Hr), F-waves, the Ashworth scale for clinical
spasticity, the Five Minutes Walking test and the Spastic Paraplegia Rating Scale (SPRS) were assessed.
Patients were evaluated before tsDCS (T0), at the end of the stimulation (T1), after one week (T2), one month
(T3) and two months (T4).
Results: The score of the Ashworth scale improved in the anodal compared with sham group, up to two months
following the end of stimulation (T1, P = .0137; T4, P = .0244), whereas the Five Minutes Walking test and SPRS
did not differ between the two groups. Among neurophysiological measures, both anodal and sham tsDCS left
Hr, F-waves and MEPs unchanged over time.
Conclusions: Anodal tsDCS significantly decreases spasticity and might be a complementary strategy for the
treatment of spasticity in HSP.
Keywords:Hereditary spastic paraplegias, Movement disorders, Spasticity treatment, Transcutaneous spinal direct current stimulation, Non-invasive spinal stimulation
Introduction
Hereditary spastic paraplegias (HSP) represent a hetero-
geneous group of neurodegenerative diseases character-
ized by progressive spasticity and lower limb weakness,
rarely involving all four limbs and variably associated
with non-motor symptoms, ranging from sensory
disturbances to cognitive impairment, epilepsy and cer-
ebellar dysfunction.1,2 HSP may be inherited by an
autosomal or X-linked modality. Approximately 50
loci have been mapped so far; three of them representing
approximately 50% of all mutations, SPG4 being the
cause in 40%, SPG3 in 10% and SPG31 in 5% of all
families studied. There were no significant associations
between disease progression with genotype, but with
the age at onset: in particular, for patients with SPG4
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mutations, disease progression was worst in late-onset
disease.3 From a pathophysiological point of view,
both the corticospinal tract axons and ascending lemnis-
cal fibers were impaired.4–6 Although the corticospinal
tract to the upper limbs is likely spared,7 supraspinal
disease mechanisms may contribute to the pathology,
exerting changes in interhemispheric processing and
intracortical excitability.8,9 To date, the treatment has
been exclusively symptomatic and no conclusive guide-
lines exist to date. Spasticity may benefit from daily
physical therapy, or from baclofen or intramuscular
injections of botulinum toxins A/B.10
Transcutaneous spinal direct current stimulation
(tsDCS) has been introduced as a non-invasive tech-
nique for modulating spinal cord function in animals
and humans.11–19 In particular, tsDCS has been used
both for interfering with the maladaptive phenomena
taking place in spinal cord-injured patients20 and
improving the effects of robotic gait-training in
chronic stroke patients.21 Interestingly, although the
mechanisms of action have only partly been elucidated,
they likely rely both on spinal and supraspinal targets,
thus possibly modulating GABA(a)ergic intracortical
networks and interhemispheric balance.22–24 Different
from transcranial direct current stimulation (tDCS),
anodal tsDCS has probably an overall inhibitory effect
on spinal cord activity: in particular, anodal polariz-
ation could act directly on corticospinal descending
pathways, without changes in postsynaptic motor neur-
onal excitability, while cathodal stimulation seems to
interfere with interneuronal networks.11–14
The aim of this study was to evaluate the effects of
tsDCS on spasticity in patients affected by hereditary
spastic paraplegias. We mainly focused our attention
on spasticity as HSP affects the long tracts with preva-
lent involvement of the longest upper motor neuron
axons, whereas the extension of the damage to the
lower motor neuron is extremely variable. To this end,
we assessed changes in clinical scores (Ashworth scale,
Five Minutes Walking test, Spastic Paraplegia Rating
Scale), motor-evoked potentials (MEPs), H-reflex and
F-waves in HSP patients who underwent lower thoracic
anodal and sham tsDCS.
Materials and methods
Subjects
Eleven patients diagnosed as having HSP were enrolled
in the study (six men and five women, mean age ± SD:
37.3 ± 8.1 years); eight were affected by spastin/SPG4
(four men), one man by atlastin1/SPG3a, one woman
by paraplegin/SPG7 and one man by ZFYVE26/
SPG15. Each patient signed an informed consent
before the inclusion in the study. The protocol was
approved by the local ethical committee, in accordance
with the tenets of the Declaration of Helsinki. The
exclusion criteria were pregnancy, skin lesions of the
stimulation area, pacemakers or other electronic
devices, previous dorsal laminectomy and other neuro-
logical disease.
Different neurologists, blinded to the tsDCS con-
dition, performed the screening visit for study enrolment
whereas the clinical and electrophysiological examin-
ation was performed by two other neurologists, both
blinded to the tsDCS condition.
This study follows the CONSORT guidelines, accord-
ing to the 25-items checklist and to the flow diagram of
the statement.
Transcutaneous spinal DC stimulation (tsDCS)
With participants lying supine on a couch, tsDCS
(2.0 mA, 20 min) was delivered by a programable stimu-
lator (HDCStimTM, Newronika, Italy) connected to a
pair of rectangular electrodes, one placed over the
spinous process of the tenth thoracic vertebra (from
the 10th to 12th vertebra, with the major axis parallel
to spinal cord) and the other above the right
shoulder.16,25 The tsDCS electrodes were rectangular
pieces of saline-soaked synthetic sponge (7 × 8 cm,
56 cm2 on the thoracic spinal cord, and 8 × 10 cm,
80 cm2 above the right shoulder). We applied a current
density of 0.035 mA/cm2 and delivered a total charge
density of 42.8 mC/cm2, below the threshold values
for tissue damage.26,27 tsDCS polarity referred to the
electrode over the spinal cord; by analogy with tDCS,
the return electrode was placed over the shoulder, as it
reduces interference between anodal and cathodal
effects.
At the onset of tsDCS, the current was increased for
thirty seconds and, at the offset, it was decreased for
thirty seconds in a ramp-like manner, a method shown
to achieve a good level of blinding among sessions.
For a sham tsDCS, the current was turned on for five
seconds and then turned off in a ramp-shaped fashion,
thus inducing skin sensations indistinguishable from
anodal tsDCS.
Patients were blinded to the tsDCS protocol and did
not discriminate between anodal and sham condition.
In order to report possible adverse effects, the question-
naire developed by Brunoni and colleagues was admi-
nistered to each patient.28
Clinical scales
Clinical scores were assessed before and after sham and
anodal tsDCS. Changes in the Ashworth scale were
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evaluated (six sub-items: hip extension, leg abduction,
knee flexion, knee extension, ankle flexion and ankle
extension). The Five Minutes Walking Test (5MWT)
and Spastic Paraplegia Rating Scale (SPRS) were also
assessed. For 5MWT participants walked back and
forth along a 30-m hallway, turning around cones at
each end for five minutes. They were allowed to use
their habitual assistive devices at each testing session.
Walking improvement on the 5MWT is indicated by
positive change scores (in meters). SPRS efficiently
reflects the severity of functional problems, comprising
also non-motor symptoms, and correlates with disease
duration.29 For both Walking Test and SPRS scores,
the best results reached by each patient entered the
analysis.
H-reflex
H reflex was obtained by delivering rectangular pulses
through Ag-AgCl electrodes (10-mm diameter) placed
over the tibial nerve at the popliteal fossa (interelectrode
distance 20 mm) and recorded from the soleus muscle
through Ag-AgCl surface electrodes (10-mm diameter)
placed 2 cm apart over the muscle belly. The hip was
kept semiflexed (∼110°), the knees slightly flexed
(∼150°), and the ankles in ∼10° plantar flexion.25
The current intensity was gradually enhanced to
achieve the H-reflex threshold (the minimum stimu-
lation intensity that evoked a reproducible response
higher than 50 µV), maximal H reflex (Hmax), and
maximal compound muscle action potential
(CMAPmax). In order to minimize post-activation inhi-
bition, the pulses were delivered at random time points,
ranging from 10 to 20 s. Stimulation began at 0-mA
intensity and grew in 1-mA steps up to the intensity
reaching the maximal H reflex.25 The signals were
amplified and bandpass filtered (3 Hz–3 kHz). We
assessed the H-reflex size (peak-to-peak amplitude,
mV), and we calculated the Hmax - to - CMAPmax
ratio.
F-waves
F waves were elicited with a 25% supramaximal stimu-
lation applied to the tibial nerve and recorded from
the AH muscle through a pair of 10-mm surface Ag-
AgCl electrodes in a belly-to-tendon configuration. F
waves from the abductor hallucis (AH) muscle were
obtained by 20 stimuli delivered to the ankle (1 Hz rep-
etition rate).30 In order to prove the absence of muscular
activity, we recorded the audio EMG feedback from the
same muscles used for MEP recording. The F-wave
mean latency (milliseconds), minimal latency (millise-
conds), mean amplitude (mV), and mean temporal
dispersion (milliseconds) were assessed. The filter
setting was 15–1500 Hz, and the skin temperature at
the ankle kept above 32°C.
Motor-evoked potentials (MEPs)
A detailed description of the methods used for MEPs
recording has been extensively reported elsewhere.25
Transcranial Magnetic Stimulation (TMS) was deliv-
ered by a Novametrix Magstim 200 stimulator
(Magstim, Whitland, UK) using a flat coil (outer diam-
eter 13.5 cm). The coil was ensured in a constant pos-
ition over the vertex. MEPs were recorded at rest by
two standard, non-polarizable Ag-AgCl surface elec-
trodes (diameter 10 mm; Technomed Europe), one
placed over the belly of the abductor hallucis (AH)
muscle and the other on the first metatarsophalangeal
joint of the toe. Because the AH has been used in
many TMS studies both in health and disease,31–33
we selected this muscle for our experiments. As
reported in previous studies, both legs were evaluated
separately, beginning from the right side.29 The stimu-
lation intensity was kept at 120% of resting motor
threshold (RMT).34,35 The threshold was set differently
for each side and was analyzed at each time point. The
current direction was adjusted, with current flowing in
the coil anticlockwise for right AH and clockwise for
the contralateral side.30 In order to assess MEP
changes among different time points, we delivered the
stimulation intensity used at baseline; for the assess-
ment of MEP area and amplitude, the stimulator
output was the same at each time point. Eight MEPs
were collected at 10-second intervals and averaged at
each time point. MEPs were amplified and filtered
(bandwidth 3 Hz–3 kHz; Nicolet Viking IV P).
Different variables were studied: RMT (% of stimu-
lator output), onset latency (milliseconds) and area
under the curve (mVms) of the motor response. RMT
was measured immediately at the end of stimulation
week and at each time interval (T2, T3, T4; see
below); the MEP area and latency were assessed off-
line on MEPs averaged from eight sweeps.
Experimental design
Subjects were studied before and after anodal and sham
tsDCS. Every patient received both the treatment
named anodal (A) or sham (S) session in a cross-over
design (AS or SA sequence) To assign patients to the
treatment sequence, we used an alternating allocation
design. All patients carried out two experimental con-
ditions held at least three months apart, to avoid
carry-over effects. Each session, either anodal or sham,
lasted five days a week (20’ twice a day). The clinical
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scores were assessed by a neurologist, while the electro-
physiological recordings were made by a neurologist and
technicians and their off-line evaluation by a third
examiner, all blinded to the tsDCS polarity. MEPs, H-
reflex and F-waves were derived from both sides.
Clinical scores, MEPs, H-reflex and F-waves were
assessed before tsDCS (T0), immediately at the end of
stimulation week (i.e. within few minutes following the
final tsDCS session, T1), after one week (T2), one
month (T3) and two months (T4).
No pharmacological modification was performed
during the week of tsDCS and during the three
months between the two experimental conditions.
Moreover, no other therapeutic interventions (i.e. phys-
ical therapy) were performed during the three months.
Statistical analysis
Values are reported as the mean ± standard error
(S.E.). MEP amplitudes were measured peak-to-
peak. Nonparametric analyses were used, as all data
sets did not pass the Shapiro-Wilk test for normality
(P < .05). tsDCS-induced changes in each variable
were then assessed with a Friedman test (non-para-
metric analysis on paired data) with the main factor
“time” (four levels: T1, T2, T3 and T4). In order to dis-
close significant changes at each time point between
anodal and sham tsDCS (T1, T2, T3, T4), a Wilcoxon
matched-pairs signed test was then applied. Both the
electrophysiological measures and clinical scores
were normalized to baseline before entering the analy-
sis (according to the formula (T1 – T0)/T0 * 100 +
100). Statistical significance was set at P < 0.05. The
data were analyzed using SPSS v. 21.0 for Windows
(SPSS Inc.).
Results
Electrophysiology
All patients tolerated the procedure well, without
adverse effects. They rarely reported a slight tingling
or itching sensation below the stimulating electrodes
lasting only a few seconds or disappearing just after
wetting the electrode sponges.
All patients completed the neurophysiological assess-
ment. Baseline values did not change among the differ-
ent experimental sessions (P > 0.2 for all the
comparisons made, Wilcoxon test with “stimulation”
as factor).
Anodal tsDCS did not statistically modify the MEP
variables when compared to sham group, although the
anodal polarization leads to a slight reduction in MEP
area over time (Table 1; threshold: P = 0.23; onset
latency: P = 0.27; area: P = 0.16, Friedman’s test).
None of the remaining electrophysiological measures
assessed were significantly changed following tsDCS
(P > 0.35, Friedman’s test, for all the comparisons
made: relative raw data are reported in Table 2).
Clinical evaluation
The baseline values did not change among different
experimental sessions (P > 0.2 for all the comparisons
made; Table 3).
The score of the Ashworth scale for lower limbs
improved in the anodal compared with sham group, in
particular up to two months following the end of stimu-
lation, at T1 (P = 0.0137, Wilcoxon matched-pairs
signed test) and T4 (P = 0.0244). Among the sub-
items, patients showed a significant improvement in
hip flexion (T4: P = 0.016, Wilcoxon matched-pairs
signed test) and knee extension (T2: P = 0.0156; T3:
P = 0.0078; T4: P = 0.0039, Fig. 1).
Nine patients only completed the clinical evaluation
by performing also the Five Minutes Walking Test
and the SPRS. No significant change was found when
the scores were compared, although there was a
general tendency toward improvement in the anodal
group (Five Minutes Walking test: P = 0.072,
Friedman analysis); no improvement in non-motor
symptoms was found, as assessed by the Spastic
Paraplegia Rating Scale (P = .83). the Wilcoxon
matched-pairs signed test did not reveal significant
differences between anodal and sham tsDCS at any
time point (P > .1).
Discussion
Thoracic tsDCS improved the Ashworth score in HSP
patients. To the best of our knowledge, this study is
Table 1 Changes over time in MEP parameters, recorded
from right and left side, after tsDCS. Results are reported as
mean values ± S.E.
Motor-evoked potentials
Resting motor
threshold (% of
stimulator output)
Latency
(ms)
Area
(mVms)
Anodal
(mean ± SE)
T0 82.0 ± 3.0 44.8 ± 1.2 1.5 ± 0.3
T1 84.5 ± 2.7 44.7 ± 1.1 1.1 ± 0.2
T2 82.5 ± 2.9 45.8 ± 1.3 1.3 ± 0.1
T3 82.3 ± 3.1 44.8 ± 1.4 1.3 ± 0.2
T4 86.8 ± 2.1 42.8 ± 2.2 1.4 ± 0.2
Sham
(mean ± SE)
T0 86.1 ± 2.3 44.3 ± 0.8 1.3 ± 0.2
T1 87.4 ± 1.9 44.1 ± 1.0 1.1 ± 0.1
T2 86.4 ± 1.9 44.7 ± 0.9 1.2 ± 0.1
T3 85.7 ± 2.1 46.0 ± 1.2 1.3 ± 0.2
T4 87.9 ± 2.1 43.4 ± 1.2 1.2 ± 0.2
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the first to investigate the effects of tsDCS in patients
with HSP.
Although tsDCS mechanisms of action still remain
debated, a growing body of evidence suggests that
tsDCS interferes with cortical, corticospinal, and spinal
motor output in humans.36–37 Since spinal stimulation
modulates both alpha and gamma motor neuron activity
in animals, anodal tsDCS could directly inhibit gamma
system in humans.14,38 In addition, the pre-synaptic inhi-
bition and post-activation depression induced by tsDCS
could reduce spasticity by modulating interneuronal excit-
ability.39 Spasticity is known to be associated with abnor-
mally weak presynaptic inhibition, as well post-activation
depression of synaptic actions of group Ia afferents.39–40
Conversely, depending on its polarity, tsDCS may be
also useful for the treatment of disease characterized by
abnormally strong pre-synaptic inhibition and post-acti-
vation depression such as spinal muscular atrophy.40
Cortical networks could be additional targets of
tsDCS in spasticity. The modulation of cortical
GABAergic activity by tsDCS22 could improve spasti-
city dampening the GABAergic tone, at a spinal as
well as cortical level.41–44 Further support for a com-
bined cortico-spinal modulation comes from a recent
study showing that anodal tsDCS depresses both M1-
and peripheral-evoked local field potentials (LFP) in
the dorsal horn, possibly reducing maladaptive plas-
ticity that contributes to muscle afferent fibers sprouting
and hyperreflexia.45
Among neurophysiological measures, the lack of
changes after tsDCS in the F-waves and H-reflex are
in line with those reported in healthy volunteers;25 the
absence of H-reflex changes suggests no modification
in small motor neurons, whereas the lack of F-wave
effects rules out changes both in large motor neurons
and postsynaptic excitability.46
Whereas in healthy subjects anodal tsDCS seemed
mainly to affect the RMTand cathodal tsDCS predomi-
nantly influenced the MEP area,25 in HSP patients
anodal polarization left both RMT and MEPs
unchanged. This discrepancy might be due to the
small and quite heterogeneous sample, but also to the
progressive loss of corticospinal fibers compared with
controls. Another possibility concerns a ceiling effect
obtained in patients with HSP, due to the small
number of residual fibers.
The main limitation of our study was the small
number of patients enrolled and their genetic pathophy-
siological heterogeneity. Overall, disease progression
significantly differs among various forms, as little pro-
gression is seen in some (SPG3a), while a worsening
even within few years is described in others (SPG4);3
moreover, SPG4 patients only have impaired intracorti-
cal excitability and no evidence for supra-spinal disease
mechanisms exists so far in SPG3, SPG7 and SPG15.8,9
Furthermore, among SPG4 patients, a wide range of
genetic mutations have been described so far, from
Table 2 Changes over time in F-waves and H-reflex parameters between anodal and sham tsDCS. Results are reported as raw
data ± S.E.
F-waves H-reflex
Threshold
(mA)
Minimal
latency (ms)
Mean
latency (ms)
Dispersion
(ms)
Threshold
(mA)
Latency
(ms)
Amplitude
(mV)
Ratio H/
M
Anodal
(mean ± SE)
T0 31.2 ± 2.7 52.2 ± 1.0 54.3 ± 1.1 5.0 ± 0.5 11.3 ± 0.9 30.6 ± 0.4 1.2 ± 0.6 0.1 ± 0.04
T1 27.3 ± 2.2 50.0 ± 1.1 52.3 ± 1.2 5.6 ± 0.4 16.2 ± 1.7 30.4 ± 0.5 1.1 ± 0.7 0.2 ± 0.03
T2 29.0 ± 1.9 49.7 ± 0.9 51.7 ± 0.9 5.1 ± 0.4 14.0 ± 1.4 29.8 ± 0.4 1.8 ± 0.4 0.2 ± 0.03
T3 28.2 ± 2.5 48.9 ± 1.1 51.3 ± 1.1 5.2 ± 0.3 13.0 ± 1.2 29.7 ± 0.5 3.6 ± 0.6 0.3 ± 0.04
T4 25.0 ± 2.0 49.0 ± 0.8 51.6 ± 0.9 5.2 ± 0.4 11.5 ± 1.1 29.9 ± 0.4 1.9 ± 0.5 0.2 ± 0.04
Sham
(mean ± SE)
T0 21.5 ± 3.7 48.1 ± 0.7 50.3 ± 0.7 4.4 ± 0.3 11.8 ± 0.9 30.6 ± 0.6 2.4 ± 0.7 0.3 ± 0.06
T1 19.0 ± 3.0 49.5 ± 1.0 51.3 ± 1.1 4.1 ± 0.4 13.0 ± 1.0 28.8 ± 0.5 1.9 ± 0.6 0.2 ± 0.04
T2 20.0 ± 2.1 47.3 ± 0.8 50.5 ± 0.9 5.1 ± 0.3 11.2 ± 0.7 29.1 ± 0.4 1.6 ± 0.4 0.2 ± 0.04
T3 20.5 ± 1.8 47.7 ± 0.8 50.6 ± 0.9 5.3 ± 0.7 12.2 ± 0.7 28.4 ± 0.5 2.0 ± 0.5 0.3 ± 0.04
T4 21.3 ± 3.8 48.3 ± 0.8 50.6 ± 0.8 6.0 ± 0.6 10.2 ± 0.9 28.4 ± 0.5 2.2 ± 0.6 0.2 ± 0.05
Table 3 Changes in total Ashworth score, 5MWTand SPRS, at
baseline and at different time points after tsDCS, following
anodal and sham tsDCS. Because the raw data did not assume
normality, the results are reported here as mean values and
interquartile range (IQR). 5MWT: the 5 Minutes Walking Test;
SPRS: Spastic Paraplegia Rating Scale.
Ashworth
score 5MWT SPRS
Anodal (mean
and interquartile)
T0 21.4 ± 10.5 18.6 ± 13.6 17.0 ± 12.4
T1 17.8 ± 9.5 19.5 ± 12.2 18.8 ± 12.6
T2 19.7 ± 10.0 18.6 ± 5.4 15.2 ± 5.4
T3 17.9 ± 7.5 17.8 ± 13.8 18.6 ± 13.4
T4 16.9 ± 6.5 18.6 ± 13.6 15.9 ± 11.0
Sham (mean and
interquartile)
T0 21.3 ± 5.5 22.3 ± 15.5 20.2 ± 13.3
T1 20.1 ± 7.5 22.8 ± 17.8 19.8 ± 12.1
T2 19.6 ± 5.5 23.0 ± 17.8 18.1 ± 9.8
T3 19.8 ± 5.0 19.1 ± 16.5 17.0 ± 12.4
T4 20.0 ± 8.0 21.0 ± 14.8 18.3 ± 13.5
Ardolino et al. tsDCS in HSP
The Journal of Spinal Cord Medicine 2018 5
large deletions to nonsense and missense mutations,
associated with different disease courses. This hetero-
geneity could explain the relative increase in Ashworth
scores at T1 and T4, as observed in the sham group com-
pared with anodal polarization, due to some patients
worsened faster than others. Finally, the effects of
direct spinal polarization on non-motor features were
not assessed in our study; it is important especially in
complex recessive spastic paraplegias, as spatacsin/
SPG11, ZFYVE26/SPG15 and paraplegin/SPG7.47
From a statistical point of view, although a crossover
study does not require a specific number of patients in
each group, it was not possible to counterbalance for
eleven patients as this number is not a multiple of the
two experimental conditions.
Conclusions
This study is the first to investigate the effects of tsDCS
in patients with HSP. The results are in line with pre-
vious data on spinal cord injuries20 and chronic
stroke,21 thereby confirming the efficacy of tsDCS for
the treatment of spasticity. Our results may, therefore,
contribute to the design of more specific applications
in clinical practice; in particular, the use of a combined
transcranial and spinal stimulation strategy would be of
interest in the wide field of movement disorders, possibly
improving motor recovery, as seen in animals.48
Moreover, as the improvement lasts up to two month
(T4) with a subsequent worsening of clinical scores,
future studies should provide more frequent stimulation
cycles. Another critical point to be assessed in future
studies is the target of tsDCS; a combined spinal and
cortical stimulation protocol to improve the clinical
outcome should be evaluated. Lastly, as in other
human diseases, the optimal tsDCS repetition rate and
duration to promote clinical improvements remains
unknown.
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